Benitec Biopharma Limited

Benitec Limited (ASX:BLT) (PINK:BNIKF) is pleased to release Chairman address to 2010 Annual General Meeting.

Benitec Limited (ASX:BLT) (PINK:BNIKF), the , the leading company in expressed gene silencing for human therapeutics, announced today that the United States Patent and Trademark Office (USPTO) has issued an official Notice of Intent to Issue an Ex Parte Re-examination Certificate for US Patent 6,573,099 ("the '099 Graham Patent"), the wide-ranging platform technology patent covering the use of expressed RNAi in human therapeutic applications.

Benitec Limited (ASX:BLT) (PINK:BNIKF), the leading company in expressed gene silencing for human therapeutics, announced today that it has been notified overnight by UK patent attorneys that the United Kingdom Intellectual Property Office (UKIPO) has received an application to revoke Benitec's exclusively licensed patent UK Patent no. 2,353,282. The application to revoke was filed by a UK-based patent attorney firm, which may be acting on behalf of a third party who are not disclosed in the application.

Benitec Limited (ASX:BLT) (PINK:BNIKF) has lodged its Statement of Cash Flows for the quarter ended 30 September 2010, showing operating cash outflows of $615,000 and cash at the end of the quarter of $556,000. During the quarter, the Company received funding from the convertible note facility with La Jolla Cove Investors, Inc of $548,000.

Benitec Limited (ASX:BLT) (PINK:BNIKF) is pleased to announce that it has commenced an R&D program to develop an expressed RNAi product for chronic intractable pain associated with diseases such as cancer and HIV.

Benitec Limited (ASX:BLT) (PINK:BNIKF) are pleased to provide this further update on the United States Patent and Trademark Office's (USPTO) Board of Patent Appeals and Interferences decision ("the Decision") reversing all previous rejections in the US 6,573,099 (the '099 Graham patent) appeal.

Benitec Limited (ASX:BLT) (PINK:BNIKF) are delighted to announce that the United States Patent and Trademark Office's (USPTO) Board of Patent Appeals and Interferences has issued a decision reversing all previous rejections in the US 6,573,099 (the '099 Graham patent) appeal.

Benitec Limited (ASX:BLT) (PINK:BNIKF), a leading Australian based company specialising in RNA interference (RNAi) technology, is pleased to announce that the US patent application for "RNAi Expression Constructs" has been successfully granted by the United States Patent and Trademark Office (USPTO) as US Patent No. 7,803,611.

Benitec Limited (ASX:BLT) (PINK:BNIKF), a leading Australian based company specialising in RNA interference (RNAi) technology, is pleased to announce a strategy update and broadening of its R&D pipeline following the recent Board and management changes announced earlier this year.

The Directors of Benitec Limited (ASX:BLT) (PINK:BNIKF) are pleased to provide this update on the progress of the patent family "Control of Gene Expression". The "Control of Gene Expression" patents are part of the foundational Graham RNAi patent family. CSIRO and Benitec have received a Notice of Allowance issued by the United States Patent and Trademark Office (USPTO) on 2 September 2010, allowing US patent application 10/759,841 "Synthetic Genes and Genetic Constructs comprising the same".